On April 1, 2016, the pan-Canadian Pharmaceutical Alliance (pCPA) issued the First Principles for Subsequent Entry Biologics (SEBs) to guide negotiations and inform expectations. These principles are now available on the pCPA website, found here.

The pCPA has also updated the status of negotiations on brand name drugs, included in their now available March 2016 update.

As of March 31, 2016:

• 22 negotiations are currently underway with one file added since the last update on February 29, 2016 –  Jardiance (empagliflozin) used to treat Type 2 diabetes;
• 100 joint negotiations have been completed with 4 files completed since the last update on February 29, 2016 – Inspiolto Respimat (tiotropium/olodaterol), Prezcobix (darunavir/cobicistat), Spiriva Respimat (tiotropium) and Zaxine (rifaximin);
• 5 negotiations have been closed as agreements were not reached with 2 files closed since the last update on February 29, 2016 – Daklinza (daclatasvir) and Soliris (eculizumab) used to treat aHUS;
• 37 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level with no new files added since the last update on February 29, 2016; and
• 12 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update on February 29, 2016.

For more information, please consult the pCPA’s website.